Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRL_Tocilizumab vs RoActemra in RA (SC, add-on to methotrexate)
2022-501361-44-00Phase 3Withdrawn
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Change in DAS28-ESR from baseline to Week 13 (EMA primary endpoint). Planned start Oct 2023; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-501361-44-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501361-44-00.